US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
WO1986006101A1
(en)
|
1985-04-12 |
1986-10-23 |
Genetics Institute, Inc. |
Novel procoagulant proteins
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
WO1987004187A1
(en)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5610278A
(en)
|
1986-06-24 |
1997-03-11 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
CA1331157C
(en)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
ATE135370T1
(de)
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
JP3045539B2
(ja)
|
1989-02-21 |
2000-05-29 |
ワシントン ユニバーシティ |
改変型生殖ホルモン
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
WO1992016221A1
(en)
|
1991-03-15 |
1992-10-01 |
Synergen, Inc. |
Pegylation of polypeptides
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US6376463B1
(en)
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
US5859204A
(en)
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
AU2001259063A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
ATE489395T1
(de)
|
2000-12-12 |
2010-12-15 |
Medimmune Llc |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
EP1463751B1
(en)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
ES2381617T5
(es)
|
2002-08-14 |
2016-02-24 |
Macrogenics, Inc. |
Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
|
EP2042517B1
(en)
|
2002-09-27 |
2012-11-14 |
Xencor, Inc. |
Optimized FC variants and methods for their generation
|
PT1562972E
(pt)
|
2002-10-15 |
2010-11-10 |
Facet Biotech Corp |
Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
DE602005015542D1
(de)
|
2004-01-12 |
2009-09-03 |
Applied Molecular Evolution |
Varianten der fc-region
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
DK2363414T3
(da)
|
2004-11-12 |
2022-08-08 |
Bayer Healthcare Llc |
Stedstyret modifikation af FVIII
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
CN101406105B
(zh)
|
2006-03-13 |
2010-11-10 |
皇家飞利浦电子股份有限公司 |
用于固态照明系统的自适应控制装置和方法
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
JP5448839B2
(ja)
|
2006-12-22 |
2014-03-19 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
インビボで長い半減期を有する修飾された凝固因子
|
EP2486936A1
(en)
|
2007-06-13 |
2012-08-15 |
CSL Behring GmbH |
A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
|
ATE502114T1
(de)
|
2007-06-21 |
2011-04-15 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
AU2009262476C1
(en)
|
2008-06-24 |
2016-06-02 |
Csl Behring Gmbh |
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
KR101544245B1
(ko)
|
2009-02-03 |
2015-08-12 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
|
NO2440241T3
(es)
|
2009-06-08 |
2018-01-06 |
|
|
CA2764108A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
EP3222287A1
(en)
|
2009-08-24 |
2017-09-27 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
PT2482841T
(pt)
|
2009-10-02 |
2019-03-01 |
Childrens Hospital Philadelphia |
A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
|
EP4169525A1
(en)
*
|
2011-07-08 |
2023-04-26 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
US9394353B2
(en)
|
2011-10-18 |
2016-07-19 |
Csl Limited |
Method for improving the stability of purified factor VIII after reconstitution
|
DK2802668T3
(en)
|
2012-01-12 |
2018-11-19 |
Bioverativ Therapeutics Inc |
METHODS FOR REDUCING IMMUNOGENICITY AGAINST FACT VIII OF INDIVIDUALS THAT UNDERSTAND FACT VIII THERAPY
|
BR112014017165B1
(pt)
|
2012-01-12 |
2023-05-02 |
Bioverativ Therapeutics Inc |
Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
|
WO2013120939A1
(en)
|
2012-02-15 |
2013-08-22 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
SI2814840T1
(sl)
|
2012-02-15 |
2020-06-30 |
Bioverativ Therapeutics Inc. |
Sestavki faktorja VIII in postopki njihove izdelave in uporabe
|
DK2882450T3
(da)
*
|
2012-07-11 |
2020-02-24 |
Bioverativ Therapeutics Inc |
Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
|
LT2968477T
(lt)
|
2013-03-15 |
2020-03-10 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii polipeptido kompozicijos
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
US20160229903A1
(en)
|
2013-06-28 |
2016-08-11 |
Biogen Ma Inc. |
Thrombin cleavable linker
|
SG10201913738YA
(en)
|
2013-06-28 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Thrombin cleavable linker with xten and its uses thereof
|
US10947269B2
(en)
*
|
2013-08-08 |
2021-03-16 |
Bioverativ Therapeutics Inc. |
Purification of chimeric FVIII molecules
|
EP3033097B1
(en)
*
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
PT4176894T
(pt)
*
|
2014-01-10 |
2024-05-21 |
Bioverativ Therapeutics Inc |
Proteínas quiméricas de fator viii e utilizações destas
|
CN106414492B
(zh)
|
2014-06-06 |
2021-07-06 |
奥克塔法马股份有限公司 |
包含因子viii和冯·维勒布兰德因子肽的制剂
|
EP3164150B1
(en)
|
2014-07-02 |
2020-11-04 |
CSL Behring Lengnau AG |
Modified von willebrand factor
|
US20170209546A1
(en)
|
2014-07-25 |
2017-07-27 |
Csl Behring Gmbh |
Improved factor viii preparations suitable for therapeutic use and processes to obtain these
|
BR112017002781A2
(pt)
|
2014-08-13 |
2017-12-19 |
Sabatino Denise |
cassete de expressão aprimorado para acondicionamento e expressão de variantes do fator viii para o tratamento de distúrbios de hemostasia
|
WO2016142288A1
(en)
|
2015-03-06 |
2016-09-15 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
SG11201708755WA
(en)
|
2015-05-22 |
2017-12-28 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
CN108779165B
(zh)
|
2016-01-07 |
2022-12-02 |
康诺贝林伦瑙有限公司 |
突变的冯·维勒布兰德因子
|
AU2017204955B2
(en)
|
2016-01-07 |
2021-04-01 |
CSL Behring Lengnau AG |
Mutated truncated von Willebrand Factor
|
EP3476937A4
(en)
|
2016-06-24 |
2019-12-04 |
Mogam Institute for Biomedical Research |
CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
|
KR20190073576A
(ko)
|
2016-11-11 |
2019-06-26 |
체에스엘 베링 렝나우 아게 |
혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|